에스테틱 엑소좀 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 공급원별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Aesthetic Exosomes Market Summary

The global aesthetic exosomes market size was valued at USD 39.7 million in 2025 and is projected to reach USD 139.8 million by 2033, growing at a CAGR of 18.0% from 2026 to 2033. The industry growth is driven by increasing demand for non-invasive, biologically active treatments. Exosomes are nano-sized extracellular vesicles naturally released by cells, playing a key role in cell-to-cell communication and tissue repair.

In aesthetics, they are primarily used for skin rejuvenation, anti-aging, scar reduction, and hair restoration. Unlike traditional cosmetic ingredients, exosomes deliver growth factors, proteins, and genetic material that actively influence skin regeneration processes, positioning them as a next-generation solution in dermatology and cosmetic procedures. One of the primary drivers of market growth is the rising demand for non-invasive and regenerative aesthetic treatments. Consumers are increasingly shifting away from surgical procedures toward minimally invasive solutions that offer faster recovery and natural-looking results. In May 2025, Mayo Clinic highlighted the development of platelet-derived exosomes as a breakthrough in aesthetic medicine, supporting their use as a topical regenerative therapy to improve skin quality and hair health. The innovation focuses on clinically processed, cell-free exosome technology that delivers consistent and measurable biological activity. Clinical observations showed that these exosomes can enhance skin texture, stimulate collagen production, and significantly reduce healing time after aesthetic procedures. This aligns with a broader industry shift toward "regenerative aesthetics," where treatments focus on stimulating the body's own repair mechanisms rather than altering appearance artificially.

Another key growth factor is the strong scientific evidence supporting the benefits of skin rejuvenation. In February 2026, a systematic review published in the National Library of Medicine evaluated the clinical efficacy of exosome-based therapies for skin rejuvenation, analyzing 19 human studies. The study reported that exosome treatments showed promising short-term improvements in skin hydration, elasticity, wrinkles, pigmentation, and overall appearance, with a generally favorable safety profile for topical use. However, the research also highlighted the need for standardized protocols and long-term clinical data to validate widespread aesthetic applications. These outcomes are largely attributed to increased collagen and elastin synthesis, along with reduced oxidative stress in skin cells. Such findings are strengthening clinician confidence and encouraging wider adoption in professional aesthetic practices.

Exosomes improve multiple skin concerns, such as fine lines, pigmentation, and laxity, in a single treatment. They support natural repair processes, aligning with demand for subtle, non-surgical rejuvenation.

A further important driver is the growing consumer awareness and demand for anti-aging solutions. Exosomes have gained attention for their ability to target multiple skin concerns simultaneously, including fine lines, pigmentation, inflammation, and texture. The key market players are continuously focusing on developing new products to fulfill the market demand. For instance, in December 2025, Le-Vel announced the launch of its XERA exosome-powered skincare system, incorporating advanced engineered exosome technology to enhance skin repair, regeneration, and anti-aging performance. The system is designed to activate the skin's natural healing processes through biomimetic signaling, representing a shift toward lab-developed regenerative skincare solutions. This launch highlights the growing commercialization of synthetic and engineered exosome-based cosmetic platforms.

In addition, increasing use in adjunct aesthetic procedures and availability of innovative & advanced exosome-based aesthetic products are further accelerating market expansion. For instance, in June 2025, PYFAESTHETIC announced the launch of its synthetic small extracellular vesicle (sEV)-based skincare product, NEOFOUND BIOS, at AMUSE 2025, marking a significant advancement in exosome-inspired aesthetics. The product utilizes lab-engineered exosome-like vesicles combined with biomimetic actives to enhance skin regeneration, improve texture, and support collagen and elastin production. This launch highlights the industry shift toward synthetic, non-biological exosome technologies offering improved stability, safety, and scalability for aesthetic applications.

Moreover, Exosomes are widely used alongside treatments such as microneedling, laser resurfacing, and chemical peels to enhance outcomes and reduce downtime. Clinical insights suggest that their application post-procedure improves recovery speed and treatment efficacy by promoting faster tissue repair. This complementary role is encouraging dermatologists and aesthetic practitioners to integrate exosomes into standard treatment protocols, thereby increasing procedural demand and product consumption.

Global Aesthetic Exosomes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global aesthetic exosomes market report based on product, source, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Topical formulations
• Injectable exosome solutions
• Source Outlook (Revenue, USD Million, 2021 - 2033)
• Human-derived exosomes
• Plant-derived exosomes
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Skin rejuvenation & anti-aging
• Acne scar treatment
• Hair restoration (androgenetic alopecia)
• Wound healing & post-procedure recovery
• Pigmentation & skin brightening
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• MedSpas
• Hospitals
• Dermatology Centers
• Homecare
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Thailand
  • Australia
  • India
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Source
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Source outlook
  • 2.2.3. Application outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Aesthetic Exosomes Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Aesthetic Exosomes Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Aesthetic Exosomes Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Aesthetic Exosomes Market: Product Movement Analysis
• 4.3. Aesthetic Exosomes Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Topical formulations
  • 4.5.1. Topical Formulations Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Injectable exosome solutions
  • 4.6.1. Injectable Exosome Solutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Aesthetic Exosomes Market: Source Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Aesthetic Exosomes Market: Source Movement Analysis
• 5.3. Aesthetic Exosomes Market by Source Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Human-derived exosomes
  • 5.5.1. Human-derived Exosomes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Plant-derived exosomes
  • 5.6.1. Plant-derives Exosomes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Aesthetic Exosomes Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Aesthetic Exosomes Market: Application Movement Analysis
• 6.3. Aesthetic Exosomes Market by Application Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Skin rejuvenation & anti-aging
  • 6.5.1. Skin Rejuvenation & Anti Aging Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Acne scar treatment
  • 6.6.1. Acne Scar Treatment Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Hair restoration
  • 6.7.1. Hair Restoration Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Wound healing & post-procedure recovery
  • 6.8.1. Wound Healing & Post-Procedure Recovery Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Pigmentation & skin brightening
  • 6.9.1. Pigmentation & Skin Brightening Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Aesthetic Exosomes Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Aesthetic Exosomes Market: End Use Movement Analysis
• 7.3. Aesthetic Exosomes Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. MedSpas
  • 7.5.1. MedSpas Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Hospitals
  • 7.6.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Dermatology Centers
  • 7.7.1. Dermatology Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Homecare
  • 7.8.1. Homecare Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Aesthetic Exosomes Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Regional Aesthetic Exosomes Market Movement Analysis
• 8.3. Aesthetic Exosomes Market: Regional Estimates & Trend Analysis by Product & Source
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. North America
  • 8.5.1. North America Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. U.S. Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. Canada Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Mexico Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Europe
  • 8.5.6. Europe Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. UK
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement scenario
    • 8.5.7.5. UK Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Germany
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement scenario
    • 8.5.8.5. Germany Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. France
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement scenario
    • 8.5.9.5. France Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.10. Italy
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Reimbursement scenario
    • 8.5.10.5. Italy Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.11. Spain
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Reimbursement scenario
    • 8.5.11.5. Spain Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.12. Denmark
    • 8.5.12.1. Key Country Dynamics
    • 8.5.12.2. Competitive Scenario
    • 8.5.12.3. Regulatory Framework
    • 8.5.12.4. Reimbursement scenario
    • 8.5.12.5. Denmark Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.13. Sweden
    • 8.5.13.1. Key Country Dynamics
    • 8.5.13.2. Competitive Scenario
    • 8.5.13.3. Regulatory Framework
    • 8.5.13.4. Reimbursement scenario
    • 8.5.13.5. Sweden Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.14. Norway
    • 8.5.14.1. Key Country Dynamics
    • 8.5.14.2. Competitive Scenario
    • 8.5.14.3. Regulatory Framework
    • 8.5.14.4. Reimbursement scenario
    • 8.5.14.5. Norway Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. Japan Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. China Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. India Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. South Korea Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement scenario
    • 8.6.6.5. Australia Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement scenario
    • 8.6.7.5. Thailand Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Brazil Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement scenario
    • 8.7.3.5. Argentina Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. South Africa Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. Saudi Arabia Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement scenario
    • 8.8.4.5. UAE Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement scenario
    • 8.8.5.5. Kuwait Aesthetic Exosomes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Croma Pharma
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Product Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. JDBIO Co
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Product Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Cartessa Aesthetics
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Product Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. BIO-FD&C
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Product Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. ExoCoBio, Inc. (Benev Therapeutics)
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Product Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Kimera Labs
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Product Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. AnteAGE
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Product Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. ExoCel Bio
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Product Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. Rion Aesthetics, Inc.
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Product Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. Brexogen
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Product Benchmarking
    • 9.2.10.4. Strategic Initiatives
    • 9.2.10.5. Strategic Initiatives